Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 10-19

  Bray, Mike ^a,c   Martinez, Mark ^a   Smee, Donald F ^b   Kefauver, Debbie ^a   Thompson, Elizabeth ^a   Huggins, John W ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c USAM RIID   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; COWPOX; COWPOX VIRUS; DRUG EFFICACY; FEMALE; LUNG HEMORRHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS VIRULENCE;

ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; ANTIVIRAL AGENTS; BRONCHI; COWPOX; CYTOSINE; FEMALE; HEMORRHAGE; MICE; MICE, INBRED BALB C; MICE, SCID; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PNEUMONIA; PULMONARY ALVEOLI; SMALLPOX; VACCINATION;

EID: 0033964541     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315190     Document Type: Article

References (41)

1. 1. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988.
2. 2. Henderson DA. Bioterrorism as a public health threat. Emerg Infect Dis 1998;4:488-92.
3. 3. Heymann DL, Szczeniowski M, Esteves K. Re-emergence of monkeypox in Africa: a review of the past six years. Br Med Bull 1998;54:693-702.
4. 4. Jezek Z, Szczeniowski M, Paluku KM, Mutombo M. Human monkeypox: clinical features of 282 patients. J Infect Dis 1987;156:293-8.
5. 5. Breman J, Henderson DA. Poxvirus dilemmas - monkeypox, smallpox and biological terrorism. N Engl J Med 1998;339:556-9.
6. 6. Wehrle PF, Posch PJ, Richter KH, Henderson DA. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ 1970;43: 669-79.
7. 7. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir Chem Chemother 1997;8:1-23.
8. 8. Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Cidofovir, a new agent with potent anti-herpesvirus activity. Antivir Chem Chemother 1996; 7:115-27.
9. 9. Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 1993; 41:242-6.
10. 10. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, Rosenberg I, Holy A. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987;8:261-72.
11. 11. Neyts J, Sobis H, Snoeck R, Vandeputte M, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. Eur J Clin Microbiol Infect Dis 1993;12:269-79.
12. 12. De Clercq E, Holy A. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob Agents Chemother 1991;35:701-6.
13. 13. Boyle JJ, Haff RF, Stewart RC. Evaluation of antiviral compounds by suppression of tail lesions in vaccinia-infected mice. Antimicrob Agents Chemother 1966;6:536-9.
14. 14. De Clercq E, De Somer P. Effect of interferon, polyacrylic acid and polymethacrylic acid on tail lesions in mice infected with vaccinia virus. Appl Microbiol 1968;16:1314-9.
15. 15. De Clercq E, Luczak M, Shugar D, Torrence PF, Waters JA, Witkop B. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc Soc Exp Biol Med 1976;151:487-90.
16. 16. Tseng CKH, Marquez VE, Fuller RW, et al. Synthesis of 3 deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem 1989;32:1442-6.
17. 17. Tignor GH, Kende M, Hanham CA. Chemotherapeutic prevention of complications caused by vaccinia virus-vectored immunogen. Ann NY Acad Sci 1992;653:334-43.
18. 18. Williamson JD, Reith RW, Jeffrey LJ, Arrand JR, Mackett M. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 1990;71:2761-7.
19. 19. Fenner F, Wittek R, Dumbell KR. The orthopoxviruses. New York: Academic Press, 1986.
20. 20. Mims C. The response of mice to the intravenous injection of cowpox virus. Br J Exp Pathol 1968;49:24-32.
21. 21. Thompson JP Turner PC, Ali AN, Crenshaw BC, Moyer RW. The effects of serpin gene mutations on the distinctive pathobiology of cowpox and rabbitpox virus following intranasal inoculation of adult mice. Virology 1993;197:328-38.
22. 22. Cox CS. The aerobiological pathway of micro.organisms. Chichester, UK: John Wiley and Sons, 1987.
23. 23. May KR. The Collison nebulizer: description, performance and application. Aerosol Sci 1973;4:235-43.
24. 24. Guyton AC. Measurement of the respiratory volumes of laboratory animals. Am J Physiol 1947;150:70-7.
25. 25. Martinez M, Bray M, Huggins JW. A mouse model of aerosol-transmitted orthopoxviral disease. Arch Pathol Lab Med (in press).
26. 26. Soike KF, Huang JL, Zhang JY, Bohm R, Hitchcock MJ, Martin JC. Evaluation of infrequent dosing regimens with (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine (S-HPMPC) on simian varicella infection in monkeys. Antiviral Res 1991;16:17-28.
27. 27. Cihlar T, Votruba I, Horska K, Liboska R, Rosenberg I, Holy A. Metabolism of 1-(S)-(3-hydroxy-2-phosphonylmethoxy-propyl)cytosine (HPMPC) in human embryonic lung cells. Collection Czechoslovak Chemical Communications 1992;57:661-72.
28. 28. Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJ. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202.
29. 29. Aduma P, Connelly MC, Srinivas RV, Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 1995;47:816-22.
30. 30. Neyts J, Snoeck R, Schols D, Balzarini J, De Clercq E. Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Virology 1990;179:41-50.
31. 31. Wachsman M, Petty BG, Cundy KC, et al. Pharmacokinetics, safety and bioavailability of HPMPC (cidofovir) in human immunodeficiency virus-infected subjects. Antiviral Res 1996;29:153-61.
32. 32. Cundy KC, Li ZH, Lee WA. Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits. Drug Metab Dispos 1996;24:315-21.
33. 33. Starrett JE, Tortolani D, Hitchcock MJM, Martin JC, Mansuri MM. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res 1992;19:267-73.
34. 34. Naesens L, Balzarini J, Bischofberger N, de Clercq E. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob Agents Chemother 1996;40:22-8.
35. 35. Cundy KC, Fishback J, Shaw JP, et al. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm Res 1994;11:839-43.
36. 36. Bischofberger N, Hitchcock MJ, Chen MS, et al. 1-[((S)-2-hydroxy-2-oxo1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994;38:2387-91.
37. 37. Roberts JA. Histopathogenesis of mousepox. I. Respiratory infection. Br J Exp Pathol 1962;43:462-8.
38. 38. Westwood JCN, Boulter EA, Bowen ETW, Maber HB. Experimental respiratory infection with poxviruses. Br J Exp Pathol 1966;47:453-65.
39. 39. Lancaster MC, Boulter EA, Westwood JCN, Randles J. Experimental respiratory infection with poxviruses. II: pathological studies. Br J Exp Pathol 1966;47:466-71.
40. 40. Wallnerova Z, Mims CA. Thoracic duct cannulation and hemal node formulation in mice infected with cowpox virus. Br J Exp Pathol 1970; 51:118-29.
41. 41. Kesson AM, Ferguson JK, Rawlinson WD, Cunningham AL. Progressive vaccinia treated with ribavirin and immune globulin. Clin Infect Dis 1997;25:911-4.